Zhejiang Tianyu Pharmaceutical Co Ltd

Zhejiang Tianyu Pharmaceutical Co Ltd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.49, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.15, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. Free cash flow for the period was 82.04 million CNY, which is significantly lower than operating cash flow of 473.57 million CNY, indicating that capital expenditures consumed a large portion of operating cash. Profitability metrics show that the company's return on equity (ROE) is 3.84%, and return on assets (ROA) is 2.12%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The gross profit margin is 34.78% (1.065 billion CNY gross profit on 3.061 billion CNY revenue), which is in line with industry norms, but the operating margin of 5.52% (168.89 million CNY operating income) is relatively low, suggesting inefficiencies in cost control or pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond China. This lack of diversification increases exposure to domestic regulatory and economic risks. The company's capital expenditures were negative at -357.77 million CNY, indicating that the company is likely in a phase of asset reduction or maintenance rather than expansion. Looking ahead, the company's revenue is expected to grow, though the exact rate is not specified. The current fiscal year's outlook is positive, with analysts assigning a mean recommendation of 1.00 (strong buy), and one strong buy rating. However, the company's net cash position is negative after subtracting total debt, which could limit its ability to invest in growth opportunities without external financing. The company faces several risk factors, including liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The risk assessment highlights the need for close monitoring of the company's cash flow and debt management strategies. Recent filings and transcripts do not indicate any major events that would significantly alter the company's strategic direction or financial stability.